Clinical trials
Multiple sclerosis clinical trials
A condition in which the immune system attacks the protective covering of nerves. We’re tracking 443 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07067463RecruitingPhase 3
Testing orelabrutinib for primary progressive MS
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Pheonix, ArizonaAges 18–60 - NCT07325292RecruitingPhase 3
Frexalimab injection vs IV for multiple sclerosis
This study tests if a new injection (frexalimab) works as well as the IV version for people with relapsing or certain types of secondary progressive multiple sclerosis. It could offer a more convenient way to receive this treatment at home.
Cullman, AlabamaAges 18–60 - NCT05704361RecruitingPhase 1
Study of an experimental drug for multiple sclerosis
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
Stanford, CaliforniaAges 18–65 - NCT07111637Recruiting
AI-assisted MRI for multiple sclerosis care
This trial is testing whether an artificial intelligence tool can improve the quality of MRI scans for people with MS. It aims to make scans faster, better, and more equitable for everyone in the NHS.
LondonAges 18–99 - NCT07758270Recruiting
Brain scan study for multiple sclerosis treatment switch
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
St Louis, MissouriAges 40–70 - NCT05285891RecruitingPhase 4
Stopping ocrelizumab in early relapsing multiple sclerosis
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
New Haven, ConnecticutAges 18–55 - NCT07168772Recruiting
Probiotic supplement for multiple sclerosis
This study tests whether adding a probiotic supplement to your usual MS treatment (or to no treatment) can help manage relapsing-remitting multiple sclerosis. It aims to see if the probiotic is safe and beneficial as an add-on therapy.
Barcelona, BarcelonaAges 18–60 - NCT03600779Recruiting
Advanced MRI scan for multiple sclerosis
This study uses a special MRI scan to look at brain damage caused by multiple sclerosis (MS). It may help doctors better understand the disease and could lead to better treatments.
Marseille, PACAAges 18–45 - NCT07606742Recruiting
Exercise Training for Hispanics With Multiple Sclerosis
This study tests a culturally tailored exercise program designed specifically for Hispanic people with multiple sclerosis (MS) who have walking difficulties. The goal is to help improve walking ability and overall quality of life through a personalized exercise plan.
Houston, TexasAges 18 years+ - NCT07587125RecruitingPhase 1
CAR-T Cell Therapy for Progressive Multiple Sclerosis
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
Xi'an, ShaanxiAges 18–75 - NCT06197685Recruiting
Combining treatments to improve memory in multiple sclerosis
This trial tests a combination of two approaches to help people with MS improve memory and learning. If you have mild-to-moderate mobility issues and are not very active, you may be able to join.
East Hanover, New JerseyAges 18–70 - NCT07736482Recruiting
How fatigue and disability affect obstacle stepping in MS
This study looks at how fatigue and disability affect your ability to step over an obstacle while walking—whether you are doing just that task or also doing a second task (like talking). It may help understand how MS affects everyday movement.
Afyonkarahisar, MerkezAges 18–65 - NCT07224373RecruitingPhase 1
A study of AZD0120 for multiple sclerosis
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
Tucson, ArizonaAges 18–60 - NCT06136728RecruitingPhase 3
Dalfampridine and physical therapy for walking problems in MS
This trial tests whether adding dalfampridine to physical therapy helps people with multiple sclerosis walk better. You must not already be taking dalfampridine or getting physical therapy to join.
Boston, MassachusettsAges 25–75 - NCT06433752Recruiting
Study of BRIUMVI for relapsing multiple sclerosis
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Birmingham, AlabamaAges 18 years+ - NCT03401879Recruiting
Study eye blood-flow changes in multiple sclerosis
This study measures how blood flow in the eye changes in people with relapsing-remitting multiple sclerosis (RRMS) who previously had optic neuritis. The goal is to understand eye/brain blood-flow signals and how they may relate to MS.
Vienna, AustriaAges 18 years+ - NCT03783416RecruitingPhase 1
Ixazomib safety study for people with multiple sclerosis
This early-phase study tests how safe ixazomib is for people with multiple sclerosis (MS). It focuses on targeting certain immune cells in MS and checks whether the treatment can be given safely.
London, Greater LondonAges 18–65 - NCT03900221Recruiting
Pregnancy monitoring registry for multiple sclerosis in France
This study follows people who are pregnant and have multiple sclerosis (or related conditions) to better understand what happens during pregnancy. It does not appear to test a new treatment; it mainly collects health and pregnancy information.
AmiensAges Any age - NCT03910738RecruitingPhase 2
Testosterone treatment for nerve protection and myelin repair in MS
This Phase 2 study tests whether taking testosterone (for low testosterone levels) can help protect nerves and repair myelin in people with relapsing-remitting multiple sclerosis (MS). It may be most relevant if your MS is stable and you have low blood testosterone without current androgen treatment.
BesançonAges 18–55 - NCT03981003Recruiting
Blood tests to track brain and nerve changes in MS
This study measures blood markers (from a serum blood sample) to see how nerve and brain changes relate to MS disease activity and disability over time. It may help researchers better monitor MS, especially in people followed in the OFSEP program.
AmiensAges 15 years+ - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT04121468RecruitingPhase 1/Phase 2
Metformin trial for vision nerve recovery in young people with MS
This study tests whether metformin can help “reset” damaged nerve cells in the brain and improve vision-related nerve problems in children and young adults with multiple sclerosis. Participants are assigned to metformin or a comparison treatment in a blinded (not everyone knows which) study.
Toronto, OntarioAges 10–25 - NCT04390009RecruitingEarly Phase 1
Whole-body PET scans in people with multiple sclerosis
This early study tests how whole-body PET-CT scans can be used in people with multiple sclerosis (and compares with healthy volunteers). It may help researchers understand what the scan can show in MS throughout the body.
Ladera Ranch, CaliforniaAges 25–55 - NCT04458688Recruiting
Ocrelizumab study for relapsing MS in African Americans and Caucasians
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
Detroit, MichiganAges 18–60
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Multiple sclerosis trials by city
Studies with a site in or near these metro areas.
Multiple sclerosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for multiple sclerosis?
- Yes. Clin2 currently lists 443 recruiting multiple sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis (MS) - Relapsing-remitting
- Multiple Sclerosis, Secondary Progressive
- Relapsing Multiple Sclerosis
- Multiple Sclerosis, Primary Progressive
- Progressive Multiple Sclerosis
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.